1. Metabolic Enzyme/Protease
  2. CETP

CETP

Cholesteryl ester transfer protein (CETP) is a plasma glycoprotein that promotes reverse cholesterol transport via the exchange of cholesteryl ester (CE) and triglyceride (TG) among lipoproteins. Cholesteryl ester transfer protein (CETP) promotes reverse cholesterol transport via exchange of cholesteryl ester and triglyceride among lipoproteins. CETP has a central role in lipoprotein metabolism.

CETP, a hydrophobic plasma glycoprotein, is a promising target for raising circulating HDL cholesterol (HDL-C) concentrations in humans. CETP is secreted primarily from the liver and plays a critical role in HDL metabolism by facilitating the exchange of cholesteryl esters (CE) from HDL for triglycerides (TG) in apoB-containing lipoproteins, such as LDL and VLDL.

CETP catalyses the exchange of cholesteryl ester and triglyceride between HDL and apoB containing lipoprotein particles. The role of CETP in modulating plasma HDL cholesterol levels in humans is well established and there have been significant efforts to develop CETP inhibitors to increase HDL cholesterol for the treatment of coronary artery disease.

CETP Related Products (4):

Cat. No. Product Name Effect Purity
  • HY-14950
    Dalcetrapib Inhibitor
    Dalcetrapib (JTT-705; RO-4607381) is a rhCETP inhibitor with IC50 of 0.2 (mu)M that increases the plasma HDL cholesterol.
  • HY-12090
    Anacetrapib Inhibitor
    Anacetrapib is a potent CETP inhibitor, with IC50s of 7.9±2.5 nM and 11.8±1.9 nM for rhCETP and C13S CETP mutant, respectively.
  • HY-13327
    Evacetrapib Inhibitor
    Evacetrapib is a potent and selective of CETP inhibitor, which inhibits human recombinant CETP protein (5.5 nM IC50) and CETP activity in human plasma (36 nM IC50) in vitro.
  • HY-12089
    Torcetrapib Inhibitor
    Torcetrapib(CP-529414) is a CETP inhibitor with IC50 of 37 nM, elevates HDL-C and reduces nonHDL-C in plasma.